EP2089043A2 - Verfahren zum herstellen eines mittels gegen eine infektionskrankheit - Google Patents
Verfahren zum herstellen eines mittels gegen eine infektionskrankheitInfo
- Publication number
- EP2089043A2 EP2089043A2 EP07819519A EP07819519A EP2089043A2 EP 2089043 A2 EP2089043 A2 EP 2089043A2 EP 07819519 A EP07819519 A EP 07819519A EP 07819519 A EP07819519 A EP 07819519A EP 2089043 A2 EP2089043 A2 EP 2089043A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- solution
- vortexed
- medical oxygen
- ebola
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 208000035473 Communicable disease Diseases 0.000 title claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 14
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 241001327634 Agaricus blazei Species 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 235000011197 perejil Nutrition 0.000 claims description 3
- 241000192700 Cyanobacteria Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 244000141009 Hypericum perforatum Species 0.000 claims description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000018735 Sambucus canadensis Nutrition 0.000 claims description 2
- 235000007123 blue elder Nutrition 0.000 claims description 2
- 235000007124 elderberry Nutrition 0.000 claims description 2
- 235000008995 european elder Nutrition 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 241000218206 Ranunculus Species 0.000 claims 3
- 241000208317 Petroselinum Species 0.000 claims 2
- 241000195493 Cryptophyta Species 0.000 claims 1
- 241000208829 Sambucus Species 0.000 claims 1
- 235000020759 St. John’s wort extract Nutrition 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 229940099416 st. john's wort extract Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 13
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 241000222518 Agaricus Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 240000007440 Agaricus campestris Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- the invention relates to a method for producing an agent against an infectious disease, in particular against HIV, Ebola od. Like ..
- HIV-infected persons are one of the most urgent biomedical problems of recent times. To date, it is only possible by appropriate measures, for example by the use of condoms during sexual intercourse, to avoid infection with the HIV virus. If the HIV virus is in the body, only an inhibition of its effect or spread is possible. New, promising therapies therefore relate to inhibiting the rapid proliferation of the virus in human tissue. HIV prothesis inhibitors block an important enzymatic pathway in the virus, resulting in significantly reduced viral loads, causing the continual destruction of the virus Immune system and the resulting harmful effects on human health.
- the literature discloses a variety of chemical agents used for HIV injection treatment. These include, for example, azido
- HIV inhibitors are described. All of these chemical agents have undesirable side effects that should be avoided.
- DE 693 27 236 T2 describes the use of dietary whey proteins for the treatment of HIV-seropositive individuals.
- a denatured whey protein concentrate for the manufacture of a medicament for the treatment of these individuals is described.
- the concentrate should be designed to increase T helper cell concentrations and T helper cell / T suppressor cell ratio in an HIV-positive individual.
- a particular medical oxygen is spun under pressure in a solution which contains at least one plant constituent, in particular in the form of an extract.
- Medical oxygen is used, for example, in artificial respiration and in inhalation therapies.
- oxygen must be subjected to a special preliminary process, in which this oxygen is specially purified and its aggressive action is reduced.
- the medical oxygen is vortexed into the solution for about one hour at a pressure of about two atm, so that as much oxygen as possible is introduced into the solution and this also remains in the solution.
- a physiological magnesium phosphoricum solution is preferably used.
- an extract of Afacimmune is to be used in the solution.
- Afacimmune is understood to mean the fungus Agaricus campestris, which is commonly grown on mineralized compost.
- elderberry bark / flower and / or agaricus blazei murill is used as the extract in the solution.
- the latter is the so-called almond fungus, which originally comes from the Brazilian rainforest. Hardly any fungus stimulates the immune system as effectively as the agaricus. Its content of polysaccharides, especially beta-glucans are highest compared to other medicinal mushrooms. For this reason, it is used in cancers. Furthermore, its promoting effect on blood formation in the bone marrow is known. It is also suitable for use in alleviating liver ailments and supports the spleen in its blood cleansing and defense function.
- the extract consists of St. John's wort and / or parsley juice in the solution. Especially effective is an extract of blue-green algae and / or buttercups.
- the blue-green extract should contain about 80 g of lithium per gram of dry matter.
- the caterpillar extract is prepared by pouring over gently-prized buttercups with hot aqua tridestilata and allowing the whole to be infused for seven minutes, whirling the above-mentioned medicinal oxygen especially into the caterpillar extract.
- the solution is added to the solution with the Afacimmune extract a sugar. It may be a specially treated sugar, but also normal granulated sugar.
- the extract is preferably prepared with hot aqua tridestilata.
- the latter is triple-distilled water, which is of the highest purity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006052504A DE102006052504A1 (de) | 2006-11-06 | 2006-11-06 | Verfahren zum Herstellen eines Mittels gegen eine Infektionskrankheit |
| PCT/EP2007/009490 WO2008055620A2 (de) | 2006-11-06 | 2007-10-31 | Verfahren zum herstellen eines mittels gegen eine infektionskrankheit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2089043A2 true EP2089043A2 (de) | 2009-08-19 |
Family
ID=39114577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP07819519A Ceased EP2089043A2 (de) | 2006-11-06 | 2007-10-31 | Verfahren zum herstellen eines mittels gegen eine infektionskrankheit |
Country Status (9)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8551535B1 (en) | 2012-08-06 | 2013-10-08 | Sarah McCann | Homeopathic remedies and methods for enhancing weight loss |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3936355A (en) * | 1973-11-12 | 1976-02-03 | The Regents Of The University Of California | Microorganism growth media and the stabilization thereof |
| GB2135668B (en) * | 1982-12-25 | 1986-08-13 | Takara Shuzo Co | Of4949, a physiologically active substance and derivatives thereof |
| US5456924A (en) | 1988-12-23 | 1995-10-10 | Immunotec Research Corporation Ltd. | Method of treatment of HIV-seropositive individuals with dietary whey proteins |
| GB9807781D0 (en) | 1998-04-09 | 1998-06-10 | Univ Bristol | Therapeutic agent |
| US6143780A (en) * | 1999-09-17 | 2000-11-07 | Uniroyal Chemical Company, Inc. | N-arylmethylthioanilide compounds useful for the inhibition of the replication of HIV |
| JP2002218969A (ja) * | 2001-01-26 | 2002-08-06 | Tsukuba Bio Syst:Kk | 食用菌の製造方法 |
| ITMI20011633A1 (it) * | 2001-07-27 | 2003-01-27 | San Raffaele Centro Fond | Uso di polisaccaridi batterici supersolfatati inibitori dell'hiv |
-
2006
- 2006-11-06 DE DE102006052504A patent/DE102006052504A1/de not_active Withdrawn
-
2007
- 2007-10-31 US US12/513,674 patent/US20100021556A1/en not_active Abandoned
- 2007-10-31 RU RU2009118361/15A patent/RU2009118361A/ru unknown
- 2007-10-31 ZA ZA200903936A patent/ZA200903936B/xx unknown
- 2007-10-31 EP EP07819519A patent/EP2089043A2/de not_active Ceased
- 2007-10-31 CN CN200780049262A patent/CN101686999A/zh active Pending
- 2007-10-31 CA CA002668741A patent/CA2668741A1/en not_active Abandoned
- 2007-10-31 JP JP2009535608A patent/JP2010508367A/ja active Pending
- 2007-10-31 WO PCT/EP2007/009490 patent/WO2008055620A2/de active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2008055620A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE102006052504A1 (de) | 2008-05-08 |
| CA2668741A1 (en) | 2008-05-15 |
| WO2008055620A3 (de) | 2009-03-05 |
| RU2009118361A (ru) | 2010-12-20 |
| WO2008055620A2 (de) | 2008-05-15 |
| CN101686999A (zh) | 2010-03-31 |
| ZA200903936B (en) | 2010-08-25 |
| US20100021556A1 (en) | 2010-01-28 |
| JP2010508367A (ja) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60027481T2 (de) | Zusammensetzung zur Behandlung von chronischer venöser Insuffizienz mit einem Extrakt aus Blättern von roten Weinreben | |
| DE19916352A1 (de) | Entfernung von hüllehaltigen Viren aus Blut, Plasma oder Serum | |
| DE10235465A1 (de) | Neue chinesische Kräuterzusammensetzung zur Verbesserung der Blutzirkulation sowie Verfahren zum Herstellen derselben | |
| DE3850262T2 (de) | Verfahren zur herstellung einer physiologisch aktiven substanz aus samenschalen von föhren und ein gegen infektionen aktives mittel, hauptsächlich auf der basis von diesem extrakt. | |
| DE102016002122A1 (de) | Detumeszenz-Odynolyse-Salbe | |
| KR20070070717A (ko) | 탈모 방지용 샴푸 제조방법 및 샴푸 | |
| EP2089043A2 (de) | Verfahren zum herstellen eines mittels gegen eine infektionskrankheit | |
| KR101084489B1 (ko) | 두피 보호,개선용 화장료 조성물 및 그 제조방법. | |
| CN106860509B (zh) | 筋骨草胶囊的生产工艺 | |
| WO2015018471A1 (de) | Lobbyist-zellschutz pni (psychoneuroimmunium) | |
| CN107251922A (zh) | 一种抑制苹果种植类病菌的中药组合物、其制备方法及应用 | |
| WO2006058430A1 (en) | Composition for treating hair and scalp and method for preparing same | |
| DE112012001971T5 (de) | Gewichtsreduzierendes Material | |
| CN109432005A (zh) | 一种含有海洋寡糖的过敏性皮炎喷剂 | |
| DE102007021403B4 (de) | Vollei-Zubereitung | |
| CN105691257A (zh) | 一种负离子驱蚊型汽车座椅头枕及应用该头枕的汽车座椅 | |
| DE102007042009A1 (de) | Pharmazeutische Formel zur Behandlung des erworbenen menschlichen Immundefektsyndroms (AIDS) Herstellungsprozess | |
| CN1613495A (zh) | 治疗腋臭的中药剂 | |
| DE102006031872B3 (de) | Verfahren zur Zellpräparation von mononukleären Zellen aus Knochenmark | |
| CN109394960A (zh) | 一种治疗高血压的中药组合物及其制备方法 | |
| EP2939650A1 (de) | Pflaster zur Behandlung von Dermatitis | |
| WO2002096444A2 (de) | Zusammensetzung mit therapeutischer wirksamkeit | |
| CN108498547A (zh) | 一种含蜂胶醇提液的酒及其生产方法 | |
| DE202014011069U1 (de) | Pflaster zur Behandlung von Dermatitis | |
| DE202020004830U1 (de) | Pharmazeutisch antimikrobielles Kombinationspräparat auf Zink - Nystatin - Wirkstoffbasis als immunologisch-hybridwirkendes therapeutisch präventives Arzneimittel zur oralen Einnahme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20090603 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20110315 |
|
| APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
| APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
| APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
| APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20121110 |